Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections

Clinical Microbiology and Infection

Volumn 18, Issue 1, 2012, Pages 54-60

  Ben David, D ^a   Kordevani, R ^a   Keller, N ^a   Tal, I ^a   Marzel, A ^a   Gal Mor, O ^a   Maor, Y ^a   Rahav, G ^a  

^a SHEBA MEDICAL CENTER   (Israel)

Author keywords

Bloodstream infection; Carbapenem resistance; Klebsiella pneumoniae; Outcome

Indexed keywords

CARBAPENEM; EXTENDED SPECTRUM BETA LACTAMASE;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM IDENTIFICATION; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HOSPITAL INFECTION; HUMAN; INFECTION RISK; INVASIVE PROCEDURE; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

KLEBSIELLA PNEUMONIAE;

EID: 83655201460     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03478.x     Document Type: Article

References (34)

1. Edwards JR, Peterson KD, Andrus ML, Dudeck MA, Pollock DA, Horan TC. National Healthcare Safety Network (NHSN) Report, data summary for 2006 through 2007, issued November 2008. Am J Infect Control 2008; 36: 609-626.
2. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8: 159-166.
3. MacKenzie FM, Forbes KJ, Dorai-John T, Amyes SG, Gould IM. Emergence of a carbapenem-resistant Klebsiella pneumoniae. Lancet 1997; 350: 783.
4. Bradford PA, Bratu S, Urban C et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004; 39: 55-60.
5. Villegas MV, Lolans K, Correa A et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother 2006; 50: 2880-2882.
6. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007; 51: 3026-3029.
7. Bratu S, Landman D, Haag R et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165: 1430-1435.
8. Anderson KF, Lonsway DR, Rasheed JK et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007; 45: 2723-2725.
9. Bratu S, Tolaney P, Karumudi U et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005; 56: 128-132.
10. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52: 1028-1033.
11. Borer A, Saidel-Odes L, Riesenberg K et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009; 30: 972-976.
12. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29: 1099-1106.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
14. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-332.
15. Korvick JA, Bryan CS, Farber B et al. Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother 1992; 36: 2639-2644.
16. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement (Approved standard M100-S16). Wayne, PA: The Clinical Laboratory Standards Institute, 2006.
17. Tumbarello M, Spanu T, Sanguinetti M et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50: 498-504.
18. Hindiyeh M, Smollen G, Grossman Z et al. Rapid detection of blaKPC carbapenemase genes by real-time PCR. J Clin Microbiol 2008; 46: 2879-2883.
19. Cordery RJ, Roberts CH, Cooper SJ, Bellinghan G, Shetty N. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome. J Hosp Infect 2008; 68: 108-115.
20. Kim BN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect 2002; 52: 99-106.
21. Bhavnani SM, Ambrose PG, Craig WA, Dudley MN, Jones RN. Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2006; 54: 231-236.
22. Menashe G, Borer A, Yagupsky P et al. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 2001; 33: 188-193.
23. Shay DK, Maloney SA, Montecalvo M et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis 1995; 172: 993-1000.
24. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 2006; 27: 1226-1232.
25. Kang CI, Kim SH, Kim DM et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004; 25: 860-867.
26. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60: 913-920.
27. Navon-Venezia S, Leavitt A, Schwaber MJ et al. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob Agents Chemother 2009; 53: 818-820.
28. Kitchel B, Rasheed JK, Patel JB et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009; 53: 3365-3370.
29. Endimiani A, Depasquale JM, Forero S et al. Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J Antimicrob Chemother 2009; 64: 1102-1110.
30. 2-lactamases. Clin Infect Dis 2004; 39: 31-37.
31. Rhee JY, Kwon KT, Ki HK et al. Scoring systems for prediction of mortality in patients with intensive care unit-acquired sepsis: a comparison of the Pitt bacteremia score and the acute physiology and chronic health evaluation II scoring systems. Shock 2009; 31: 146-150.
32. Thom KA, Shardell MD, Osih RB et al. Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points. Infect Control Hosp Epidemiol 2008; 29: 1048-1053.
33. Kallel H, Hergafi L, Bahloul M et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33: 1162-1167.
34. Pintado V, San Miguel LG, Grill F et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008; 56: 185-190.